TGFB1 and inflammatory bowel disease: TGF-β signalling is known to play a critical role in controlling intestinal inflammation [29–31] and indeed recently proposed therapeutic for IBD sought to enhance TGF-β activation by inhibiting its negative regulator Smad7, an inhibitor of this pathway [32].